Periorbital skin aging
Conditions
Interventions
Test group:Type A Recombinant Type III Humanized Collagen
Sponsors
Dermatology Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.Fitzpatrick skin type I-II; 2.Age 30-55 years, male or female; 3.No other treatment for periorbital fine lines within 1 year; 4.After fully understanding the treatment plan and risks, subjects voluntarily participate in this clinical trials, sign the informed consent form and cooperate with the follow-up plan.
Exclusion criteria
Exclusion criteria: 1.Subjects with severe diseases such as malignant tumors; 2.Subjects with severe systemic diseases and currently taking drugs for their systemic diseases; 3.Subjects who have received any medical aesthetic filler injection within the past 1 year; 4.Subjects who have received periorbital laser, radio frequency, ultrasound, botulinum toxin and skin-booster treatment within the past 6 months; 5.Subjects who have received any periorbital plastic surgery within the past 2 year; 6.Subjects who plan to receive any other facial medical aesthetic treatment items and drugs during this study; 7.Female subjects who are pregnant, lactating or planning to become pregnant; 8.Subjects with known intolerance or hypersensitivity to topical anesthetics; 9.Subjects with known intolerance or hypersensitivity to collagen, including (but not limited to) those who have ever been allergic to collagen products, such as injections, implants, hemostatic cotton, sutures, biological collagen glue, etc; 10.Subjects who are scar constitution, or whose periorbital skin are infected with various bacteria, fungi, viruses, etc.; 11.Subjects with Severe heart, brain, liver, kidney, lung, blood and other systemic diseases, autoimmune diseases, immunodeficiency, and generalized muscle movement disorders; 12.Subjects with any facial diseases (combined with scars, eczema, dermatitis, etc.)that affect the judgment of periorbital wrinkles, or any other diseases that can be irritated or stimulated by invasive operations (such as vitiligo, lichen planus, flat warts, precancerous or malignant skin tumor, etc.); 13.Subjects who cannot regularly participate in follow-up visits; 14.Other subjects who are not suitable for participating in this study as assessed by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in periorbital wrinkle score;Change from baseline in periorbital fine lines; | — |
Secondary
| Measure | Time frame |
|---|---|
| periorbital skin elasticity;periorbital skin firmness;periorbital skin thickness and density;GAIS score from investigator and subjects; | — |
Countries
China
Contacts
Public ContactBin Yang
Dermatology Hospital of Southern Medical University
Outcome results
None listed